Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients

J Immunother Cancer. 2022 Sep;10(9):e004902. doi: 10.1136/jitc-2022-004902.

Abstract

Cellular immunotherapies have emerged as a successful therapeutic approach to fight a wide range of human diseases, including cancer. However, responses are limited to few patients and tumor types. An in-depth understanding of the complexity and dynamics of cellular immunotherapeutics, including what is behind their success and failure in a patient, the role of other immune cell types and molecular biomarkers in determining a response, is now paramount. As the cellular immunotherapy arsenal expands, whole-body non-invasive molecular imaging can shed a light on their in vivo fate and contribute to the reliable assessment of treatment outcome and prediction of therapeutic response. In this review, we outline the non-invasive strategies that can be tailored toward the molecular imaging of cellular immunotherapies and immune-related components, with a focus on those that have been extensively tested preclinically and are currently under clinical development or have already entered the clinical trial phase. We also provide a critical appraisal on the current role and consolidation of molecular imaging into clinical practice.

Keywords: Adaptive Immunity; Immunotherapy, Adoptive; Receptors, Chimeric Antigen.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / metabolism
  • Humans
  • Immunotherapy* / methods
  • Neoplasms* / diagnostic imaging
  • Neoplasms* / therapy
  • Treatment Outcome

Substances

  • Biomarkers, Tumor